Skip to main content

GSK plc 6-K, filed Oct 21, 2026

GSK plc (GSK)

6-K 2026-10-21 For: 2026-10-21
View Original
Added on October 21, 2026

About this 6-K

GSK plc filed this 6-K on October 21, 2026.

GSK plc announced that the FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B, with phase III trials showing a 19% functional cure rate after six-month treatment versus less than 1% for standard care alone. AI summary